ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2017
Perspectives on Dual Targeting Delivery Systems for Brain Tumors.
Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Unraveling the Mysteries of Brain Cancer from Diagnosis to Treatment.Pharmaceutical nanotechnology · 2026Review
- Advancements in dual-targeting nanoparticle strategies for enhanced atherosclerosis therapy: Overcoming limitations of single-targeting approaches.Bioactive materials · 2026Review
- Engineered nanoparticles as a promising drug delivery system for glioblastoma multiforme treatment.Therapeutic delivery · 2025Review
- Nano-Encapsulated Taro Lectin Can Cross an in vitro Blood-Brain Barrier, Induce Apoptosis and Autophagy and Inhibit the Migration of Human U-87 MG Glioblastoma Cells.International journal of nanomedicine · 2025Article
- Discovery of a Novel Dual Targeting Peptide for Human Glioma: FromAdvanced pharmaceutical bulletin · 2024Article
- Novel Biomaterials Based Strategies for Neurodegeneration: Recent Advancements and Future Prospects.Current drug delivery · 2024Review
- Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure against Glioblastoma.ACS omega · 2023Article
- "Guide" of muscone modification enhanced brain-targeting efficacy and anti-glioma effect of lactoferrin modified DTX liposomes.Bioengineering & translational medicine · 2023Article
- Increased brain uptake of pterostilbene loaded folate modified micellar delivery system.Drug delivery · 2022Article
- Combinatorial therapeutic strategies for enhanced delivery of therapeutics to brain cancer cells through nanocarriers: current trends and future perspectives.Drug delivery · 2022Review
- Review
- Hybrid Membrane-Derived Nanoparticles for Isoliquiritin Enhanced Glioma Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Multimodal targeting of glioma with functionalized nanoparticles.Cancer cell international · 2022Review
- Intelligent lesion blood-brain barrier targeting nano-missiles for Alzheimer's disease treatment by anti-neuroinflammation and neuroprotection.Acta pharmaceutica Sinica. B · 2022Article
- Gather wisdom to overcome barriers: Well-designed nano-drug delivery systems for treating gliomas.Acta pharmaceutica Sinica. B · 2022Review
- The development of a redox-sensitive curcumin conjugated chitosan oligosaccharide nanocarrier for the efficient delivery of docetaxel to glioma cells.Annals of translational medicine · 2022Article
- Glymphatic System and Subsidiary Pathways Drive Nanoparticles Away from the Brain.Research (Washington, D.C.) · 2022Article
- Combined integrin αJournal of nanobiotechnology · 2021Article
- Carrier-free highly drug-loaded biomimetic nanosuspensions encapsulated by cancer cell membrane based on homology and active targeting for the treatment of glioma.Bioactive materials · 2021Article
- From blood to brain: blood cell-based biomimetic drug delivery systems.Drug delivery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain tumor remains one of the most serious threats to human beings. Different from peripheral tumors, drug delivery to brain tumor is largely restricted by the blood brain barrier (BBB). To fully conquer this barrier and specifically deliver drugs to brain tumor, dual targeting delivery systems were explored, which are functionalized with two active targeting ligands: one to the BBB and the other to the brain tumor. The development of dual targeting delivery system is still in its early stage, and attentions need to be paid to issues and concerns that remain unresolved in future studies.
Indexed as
Identifiers
27270720What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.